Alnylam PharmaceuticalsALNY
NASDAQ · USA · Segment 3 of 8 in the Medicine, pharma & life science value chain: Biotech & innovation
Pioneer of RNAi medicines for rare and cardiovascular diseases.
Biotech & innovation: Innovation-driven biotech companies focused on novel treatment modalities.
Key metrics
Market cap
$43.2B
Price
$300.04
Today
−4.1%
Return YTD
−21.3%
Return 1Y
−2.5%
P/E
74.8
P/S
10.1
P/B
40.2
Data as of 2026-07-10 · updates daily after U.S. close
Theme exposure
In the value chain
Products & services
- RNAi therapies (amyloidosis)
- Cardiovascular RNAi
- Research platform
Competitors
- Ionis Pharmaceuticals
- Pfizer
- BridgeBio
Risks
- Pipeline concentration
- Competition in rare diseases
Same segment: Biotech & innovation
See where Alnylam Pharmaceuticals sits in the full Medicine, pharma & life science map — every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →